The CSB repair factor is overexpressed in cancer cells, increases apoptotic resistance, and promotes tumor growth  by Caputo, Manuela et al.
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In  the  present  study  we show  that a number  of cancer  cell  lines  from  different  tissues  display  dramatically
increased  expression  of  the  Cockayne  Syndrome  group  B  (CSB)  protein,  a  DNA  repair  factor,  that  has
recently  been  shown  to  be involved  in  cell  robustness.  Furthermore,  we  demonstrated  that  ablation  of
this  protein  by antisense  technology  causes  devastating  effects  on  tumor  cells  through  a drastic  reductioneywords:
ockayne Syndrome group B protein
ncogene
poptosis
ancer cells
of  cell  proliferation  and  massive  induction  of  apoptosis,  while  non-transformed  cells  remain  unaffected.
Finally,  suppression  of  CSB  in  cancer  cells  makes  these  cells  hypersensitive  to  a  variety  of  commonly
used  cancer  chemotherapeutic  agents.  Based  on  these  results,  we  conclude  that  cancer  cells  overexpress
CSB  protein  in  order to enhance  their  anti-apoptotic  capacity.  The  fact that  CSB  suppression  speciﬁcally
affects  only  cancerous  cells,  without  harming  healthy  cells,  suggests  that  CSB  may  be a very  attractive
target  for the  development  of  new  anticancer  therapies.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction
Resistance to apoptosis is a fundamental characteristic of cancer
ells and the primary cause of treatment failure against this dev-
stating disease [1]. Activation of programmed cell death in cancer
ells offers novel and potentially useful approaches for improving
nticancer therapy and provides alternative tools to conventional
hemotherapy. CSB is a SWI/SNF-like DNA-dependent ATPase that
an wind DNA and remodel chromatin [2–5]. Mutations in the csb
ene give rise to Cockayne syndrome (CS), an autosomal recessive
isorder characterized by premature aging and affecting growth,
evelopment and maintenance of a wide range of tissues and
rgans [6,7]. In the context of cell metabolism, CSB plays a number
f different functions. This protein participates in the transcription-
oupled repair (TCR) sub-pathway of nucleotide excision repair
NER). TCR rapidly removes bulky DNA lesions located on the tran-
cribed strand of active genes [8]. In addition, CSB plays a role
uring transcription by stimulating all three classes of nuclear RNA
olymerases [3,9,10]. Finally, we recently demonstrated that CSB
lays a critical role in cell robustness by negatively modulating p53
ctivity after cellular stress, including DNA damage and hypoxia
∗ Corresponding author. Tel.: +39 0761357211.
E-mail address: proietti@unitus.it (L. Proietti-De-Santis).
568-7864 © 2013 Elsevier B.V. 
ttp://dx.doi.org/10.1016/j.dnarep.2013.01.008
Open access under CC BY-NC-ND license.[11]. CSB performs two main functions by counteracting p53 activ-
ity: ﬁrst, by interacting with p53, CSB releases and redistributes
the limiting transcriptional co-factor p300 acetyl-transferase to
gene expression programs with opposite purposes (pro-survival
pathways) [12]; second, CSB down-regulates the cellular levels
of p53, by stimulating its ubiquitination and degradation [13].
Accordingly, the deregulation of p53 and the subsequent enhanced
apoptotic response in the absence of the CSB protein gives rise
to the pronounced cell fragility observed in CS patients upon
exposure to stressors of a broad nature. Of interest-, we have previ-
ously shown that CSB also counteracts p53-independent apoptosis
[14].
Therefore, it seems that CSB functions as an anti-apoptotic factor
that re-equilibrates the physiological response toward cell prolifer-
ation and survival rather than cell cycle arrest and cell death upon
stress. Based on these ﬁndings, we  believe that CSB represents a
strategic target for anticancer therapy. Our hypothesis suggests that
the inhibition or down regulation of CSB in cancer cells may result
in the down regulation of pro-survival programs aimed to allow
cancer cells to evade apoptosis. In the present study we  showed
that CSB is overexpressed in a variety of cancer cell lines and tis-
sues. Importantly, the down regulation of CSB in these cancer cells
resulted in a marked increase of apoptosis. Furthermore, down reg-
ulation of CSB also made these cells hypersensitive to anti-cancer
chemotherapeutic drugs.
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. Materials and methods
.1.  Cell lines
Tumor  cell lines HeLa, MGH  and USB were grown in DMEM
ontaining 10% FCS and antibiotics. Prostate tumor cells (PC3)
ere cultured in RPMI containing 10% FCS and antibiotics. Normal
rostate epithelium cells (RWPE1) were cultured in Keratinocyte
edium (Invitrogen), with EGF (5 ng/ml) and BPE (0.05 mg/ml).
ormal primary human ﬁbroblasts (C3PV) were cultured in MEM
ontaining 15% fetal bovine serum, essential and non-essential
mino acids, vitamins and antibiotics. Breast tumor cells MCF7
ere cultured in Eagle’s MEM  containing 0.6 g/ml bovine insulin
nd 10% FBS. Breast tumor cells T47D were cultured in RPMI-
640 Medium containing 0.6 g/ml bovine insulin and 10% FBS.
on-tumorigenic breast epithelial cell line (MCF10A) was  cultured
n DMEM containing EGF (20 ng/ml), Cholera toxin (100 ng/ml),
ydrocortisone (500 g/ml), 0.01 mg/ml  bovine insulin and 5%
orse serum.
.2.  Oligonucleotides transfection
The  day before transfection, cells (1 × 105 for 6-well dishes
nd 2 ×104 for 24 well dishes) were plated using medium with-
ut antibiotics. Immediately before transfection the medium was
eplaced with Optimem and oligonucleotides (200 nM ﬁnal con-
entration) were delivered using Oligofectamine (Invitrogen, USA)
ollowing manufacturer’s instructions. At four hours Optimem was
eplaced with complete medium.
Nine different antisense oligonucleotides targeting CSB mRNA
accession number NM 000124) were used. The control oligonu-
leotides were the reverse of the antisense sequence. Oligonu-
leotide sequences are available on request.
.3. Retrotranscription and real-time quantitative PCR
RNA  was isolated using the NucleoSpin RNA II kit (Macherey-
agel). cDNA synthesis was  performed using the First Strand cDNA
ynthesis kit (Fermentas). Real-time quantitative PCR was carried
ut with SYBR green master mixture (Promega) using Mx3005P
eal-Time PCR system (Agilent). Results were normalized to beta-
ctin. Primers sequences are available on request. qPCR arrays
ontaining cDNA synthesized from RNA of cancer and normal tis-
ues were bought at Origene (TissueScanTM cDNA Array).
.4.  Site direct mutagenesis
Site  direct mutagenesis at three independent sites was  per-
ormed, one site at a time, using QuikChange XL Site-Directed
utagenesis Kit (Stratagene). As visualized in Fig. 2E (bottom
anel) the cDNA coding sequence of the CSB wt expression vec-
or has been changed at nucleotide position 3249 (A to G), 3255 (T
o G) and 3262 (A to G).
.5.  Cell viability assay
Cell  viability was evaluated using MTT  [3-(4,5-dimethylthiazol-
-yl)-2,5-diphenyl-2H-tetrazolium bromide] cell proliferation
ssay. Cells were plated in 96-well plates one day before oligonu-
leotides transfection as described above. MTT  was added to each
ell (0.5 mg/ml) at the indicated times. After incubation for 3 h at
7 ◦C, the supernatant was replaced with 150 l of solution (10%
DS, 0.6% acetic acid in DMSO) to dissolve the formazan crys-
als and produce a purple solution. Optical density measurements
ere obtained using a scanning spectrophotometer DTX 880 Mul-
imode Detector (Beckman Coulter). The readings were made usingir 12 (2013) 293– 299
a  630 nm (background) and a 570 nm ﬁlter. The assays were con-
ducted in quadruplicate for each condition.
2.6. Proliferation assay
The  day before transfection, 1 × 105 cells were plated in 6-well
plates. The cell proliferation assay was performed using 0.05% try-
pan blue solution to distinguish live and dead cells within a Burker
chamber. Three replicate counts were determined by the same
operator at each time point (at the moment of transfection and
24, 48 and 72 h later).
2.7. Apoptosis analysis
One  day before transfection, 1 ×105 cells were plated in 6-well
plates. 48 h later the oligonucleotides transfection a combination
of ﬂuorescein diacetate (FDA; 15 g/ml), propidium iodide (PI,
5 g/ml) and Hoechst (HO, 2 g/ml), were used to differentiate
apoptotic and necrotic cells from viable cells. FDA and HO are
vital dyes that stain the cytoplasm and nucleus of the viable cells,
respectively. The necrotic and the late stage of apoptotic cells are
readily identiﬁed by PI staining. Cells in the early phase (viable––HO
stained) and late phase (dead––PI stained) of apoptosis displayed
the characteristic pattern of chromatin fragmentation. Approxi-
mately 2000 randomly chosen cells were microscopically analyzed
to determine apoptosis levels.
3. Results
3.1. CSB gene is overexpressed in cancer cells
In order to assess whether CSB is overexpressed in cancer cells,
we measured CSB protein levels in a variety of tumors. We  ﬁrst
screened human cancer cell lines of various origins: bladder (MGH
and USB), cervix (HeLa), prostate (PC3) and breast (T47D and
MCF7) for CSB protein expression. These data were compared with
those obtained using normal primary ﬁbroblast (C3PV), normal
immortalized prostate epithelial cells (RWPE1) and normal non-
tumorigenic breast epithelial cells (MCF 10A). As shown in Fig. 1A
and B, western blot analysis using total cellular extracts and rel-
ative quantiﬁcation revealed an increase in CSB protein levels in
cancer cells (MGH, USB, HeLa, PC3, T47D and MCF7), compared to
normal cells (C3PV, RWPE1 and MCF  10A). Among the cancer cell
lines that we  analyzed, only two  breast cancer cell lines (ZR-75-
1 and MDA-MB-231) did not display a signiﬁcant increase in CSB
protein expression (data not shown). The similar increase in pro-
tein levels, as detected by western blot, for both full-length CSB
and the CSB/PGBD3 isoforms, in which the ﬁrst 5 exons of CSB are
alternatively spliced with the PGBD3 transposase [15], suggested
a transcriptional mechanism at the basis of their overexpression,
since both are under the control of the same promoter. Therefore,
we performed a quantiﬁcation of CSB mRNA using quantitative
real-time PCR and conﬁrmed that the elevated protein levels were
due to an increase in mRNA; all tumor cell lines analyzed dis-
played an overall increased CSB mRNA level ranging from 3 to 5
fold (Fig. 1C). We  also screened the expression of CSB mRNA in a
large variety of cancer tissues. Comparative RT-PCR gene expres-
sion analysis of array from a large variety of cancer and normal
tissues, such as breast, ovarian, lung and kidney, showed high levels
of CSB mRNA expression in several tumor tissues.
As shown in Fig. 1D, we observed a signiﬁcant overexpression
of CSB mRNA in four of ﬁve kidney and lung cancer tissue sam-
ples, while only two  of ﬁve cancer tissue samples from breast and
ovarian displayed CSB mRNA overexpression compared to the nor-
mal  tissue sample. The heterogeneous expression of CSB among the
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Fig. 1. (A) Western blot analysis showing CSB full-length, CSB-PGBD3 and actin protein levels. Actin is used as loading control. (B) Relative quantiﬁcation of CSB protein
expression obtained by normalizing CSB by b-actin protein amount. (C) qRT-PCR analysis of CSB mRNA expression. The results, normalized to b-actin, were averaged
from values obtained by performing three different experiments. Values are means ± SD. (D) Tissue Scan Cancer qPCR Arrays (Origene) containing cDNAs from normal and
different  stage cancer tissues were subjected to qRT-PCR with CSB speciﬁc primers. CSB levels were normalized to b-actin. The results were averaged from values obtained
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ach  sample are available in supplementary Fig. 1. (For interpretation of the referen
ancer tissue samples that we analyzed is in line with the extended
enetic and epigenetic heterogeneity in cancer.
.2. Inhibition of CSB mRNA expression using antisense
ligonucleotides strategy
We  have shown that CSB protein negatively modulates both
53-dependent and independent apoptosis (14). Therefore we
sked if the overexpression of CSB in cancer cells rendered these
ells resistant to apoptosis. We  decided to suppress CSB expression
nd test if the absence of CSB would render cells more sensitive to
poptotic stimuli. To inhibit CSB expression we designed antisense
ligonucleotides (ASOs) to target and induce the degradation of
ts messenger RNA (mRNA). Sense oligonucleotides (SOs) for each
arget sequence were used as control. Fig. 2A shows CSB mRNA
xpression in HeLa cells, 12 h after transfecting either antisense or
ense oligonucleotides (ﬁnal concentration 200 nM). We  selected
hree ASOs (numbers 7, 9 and 11) that resulted in the most efﬁcient
eduction of CSB mRNA expression when used in combination.
.3.  CSB suppression reduces viability and proliferation of cancer
ells
Next  we examined the impact of CSB suppression on cell viabil-
ty and proliferation in HeLa cells. Either individual or combinations
f two or three individual ASOs (7, 9 and 11) were used. Viability at
8 h post transfection was measured by MTT  assay. Results in Fig. 2B
nd C showed a dramatic reduction in viability of HeLa cells when
SB expression was suppressed. In particular the 7 + 9 + 11 combi-
ation caused a reduction around 90% of the viability compared to
he control samples that were transfected with the correspondingrmal tissues. Gray: Cancer tissues. Clinical information including disease stage for
 color in this ﬁgure legend, the reader is referred to the web version of the article.)
SOs.  Transfection of decreasing concentration of oligonucleotides
(7 + 9 + 11) showed that reduction of cell viability was  propor-
tional with the amount of ASOs used (Fig. 2D). In order to exclude
that the reduction of cell viability related to any off-target effects
instead of CSB suppression, we  performed rescue experiments with
a CSB cDNA that was  resistant to ASO. We  modiﬁed the CSB cDNA
sequence of a CSB expressing vector (pcDNA-CSB*) to perturb ASO
annealing. To minimize the mutagenesis of the cDNA sequence we
focused on the ASO11 target sequence, because it has a profound
effect on known-down and viability even when transfected alone.
As shown in Fig. 2E, re-expression of CSB* rescued cell viability illus-
trating that CSB protein is fundamental for the viability of cancer
cells overexpressing it.
Next,  we  performed the MTT  assay in the other cancer cell lines
that we  had found to overexpress CSB (MGH, USB, PC3, MCF7 and
T47D), substantially validating our ﬁndings that CSB suppression
dramatically reduced the viability of cancer cell lines characterized
by its overexpression. Importantly, the MTT  assay performed on
normal cells (C3PV, RWPE1 and MCF  10A) showed that knockdown
of CSB did not substantially affect the viability of normal cells that
were also found not to overexpress CSB (Fig. 2F).
Furthermore, inhibition of proliferation in HeLa cells, as a
function of CSB suppression, was measured by directly counting
viable cells at different times. In particular, cell counts were per-
formed at the time of transfection and 24, 48 and 72 h after the
oligonucleotides transfection (Fig. 3A). Inhibition of CSB protein
expression, using ASO 7 + 9 + 11, completely arrested cell prolifer-
ation of HeLa cells throughout the entire time course, while the
respective SOs combination did not have any effect (Fig. 3B). The
slight increase in cell proliferation as observed in the untreated
sample (k) could be due to a minimal toxicity of the transfection
reagent.
296 M.  Caputo et al. / DNA Repair 12 (2013) 293– 299
Fig. 2. (A) qRT-PCR to analyze CSB mRNA expression 12 h after transfection. The results, normalized to b-actin, were averaged from values obtained by performing three
different experiments. Values are means ± SD. (B–F) MTT  assay: (B) 96 well plate after an MTT  assay performed in HeLa cells using either sense, rows (1–3) and antisense,
rows (4–6) oligonucleotides. HeLa cells were seeded in 96 well plates in quadruplicate, 18 h later cells were transfected with sense or antisense oligonucleotides (200 nM
ﬁnal  concentration). 48 h after the transfection, MTT  absorbance was  measured as described in Section 2. (C) Graph illustrating MTT  absorbance in HeLa cell 48 h later the
transfection, cells have been treated with 200 nM oligonucleotides. In (D) HeLa cells have been treated with decreasing concentration of oligonucleotides (combination
7 + 9 + 11) and MTT  absorbance was read 48 h later the transfection. (E) CSB relative mRNA expression (12 h after the transfection; left panel) and viability (48 h later the
transfection; right panel) in HeLa cells treated with sense or antisense oligonucleotide 11 (200 nM ﬁnal concentration). Purple columns concern HeLa cells that had been
previously transfected with a three points-mutagenized CSB coding cDNA which express a transcript resistant to ASO11 degradation. (F) Graph illustrating MTT absorbance in
n  cell lin
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c
p
i
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ﬂormal  (C3PV, RWPE1 and MCF  10A) and tumoral (MGH, USB, PC3, MCF7 and T47D)
f either sense or antisense oligonucleotides (combination 7 + 9 + 11). The results we
Again, using the same assay to analyze cell proliferation, we
onﬁrmed that suppression of CSB strongly reduced the levels of
roliferation in all the cancer lines characterized by its overexpress-
on but not in the non tumorigenic normal cell lines (Fig. 3C).
To  quantitatively assess the rates of apoptosis induced by
he suppression of CSB expression, we used a combination of
uorescent dyes to analyze the morphological alterations thates 48 h later the transfection, cells have been treated with 200 nM oligonucleotides
raged from values obtained by performing three MTT arrays. Values are means ± SD.
cells  undergo during apoptosis. Fluorescein di-acetate (FDA) and
Hoechst (HO) stain the cytoplasm and the nucleus, respectively, of
viable cells. The necrotic and the late stage apoptotic cells were
stained by propidium iodide (PI), which requires the loss of the
cytoplasm and nuclear membrane integrity. As shown in Fig. 4A,
apoptotic cells were not detectable when HeLa cells were trans-
fected with SOs. In contrast, apoptotic cells were readily visible
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ig. 3. Cell proliferation assay. 1 × 105 cells have been seeded in 6-well plates and t
8,  72 h after transfection (A). The analysis was  performed in triplicate. Results hav
hen the CSB expression was suppressed by ASOs in HeLa cells. Fur-
her morphological analysis by microscopy (Fig. 4B) showed that
pproximately 55% of HeLa cells transfected with ASOs had under-
one apoptosis, while only 5% of cells transfected with SOs had
ndergone apoptosis. Again, we extended this analysis to the other
ell lines, conﬁrming that CSB suppression dramatically enhanced
poptosis in tumor but not in non-tumoral cell lines (Fig. 4C).
To  evaluate whether down-regulation of CSB sensitizes can-
er cells to conventional chemotherapy agents we  combined
SOs administration to oxaliplatin, mytomicin-C and 5-ﬂuorouracil
reatments. Cellular viability was assayed with increasing concen-
rations of CSB ASOs (50 and 100 nM)  followed by the addition of a
xed concentration of conventional chemotherapeutic agents that
e had previously found to correspond to the respective IC50 dose.
he combination of ASOs and chemotherapy agents led to a signif-
cant reduction of cell viability (additive effect) when compared
o the effect displayed when cells were treated either with the
hemotherapy agent or ASO (compare sample 2 and 10 with 6, for
nstance), while SOs did not increase cancer cell death either alone
r in combination with chemotherapy agents (Fig. 4D). Normal cells
3PV were also found not to be sensitive to single treatment (ASO
r oxaliplatin) or combined treatment, at least at the doses that we
sed in Hela cells (Fig. 4E).
. DiscussionWe  have shown that a number of cancers display overexpress-
on of CSB and that its suppression induces massive cell death via
poptosis. It is well known that the expression of oncogenes, such as
as or Myc, elicits the cell suicide machinery, a mechanism today0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 70 80 90
cted 18 h after seeding. Cells have been counted at the time of transfection and 24,
 graphed in panels B and C.
widely  accepted as an innate tumor-suppressive program. How-
ever, cancer cells evolved a mechanism to buffer this pro-apoptotic
response and to bring the cell back under the apoptotic activation
threshold [16]. We  propose that CSB may  play an important role in
this context. First, it is reasonable to believe that the function of CSB
is to control p53 activity before cancer cells acquire mutations that
permanently inactivate this tumor suppressor. Moreover, we have
previously shown that CSB also plays a role in the evasion of the
p53-independent apoptosis [14]. This suggests that overexpress-
ion of CSB may  remain fundamental to escape apoptosis even later,
when cells have eventually inactivated the p53 pathway.
Furthermore, adaptation to hypoxia is a fundamental step dur-
ing cancer progression when the tumor mass becomes larger than
2 mm,  thus it is no longer supported by the pre-existing vas-
culature and new vessels need to be generated [17]. We  have
previously shown that CSB plays a fundamental role in the HIF-1
controlled transcriptional programs [12]. CSB governs the adapta-
tion to hypoxia that also involves the triggering of extravasion and
angiogenesis, as well as the potentiation of glucose metabolism,
known as the Warburg effect [18,19]. All these processes are fun-
damental steps in cancer progression; therefore we believe that by
boosting the CSB/HIF-1 axis, cancer cells gain a growth advantage.
Moreover,  the overexpression of CSB would also confer cancer
cells an increased DNA repair capacity, which could explain the
emergence of DNA damage (and thus anti-cancer therapy) drug
resistance developed by cancer cells. Recent work has demon-
strated, for instance, that ablation of transcription coupled repair,
increased cisplatin sensitivity of several prostate and colorectal car-
cinoma cell lines with speciﬁc defects in p53 and/or DNA mismatch
repair [20]. Accordingly, our data showed that silencing of CSB
298 M.  Caputo et al. / DNA Repair 12 (2013) 293– 299
Fig. 4. (A) Images show that suppression of CSB massively induced apoptosis in HeLa cells. Apoptosis was analyzed morphologically by staining cells with ﬂuoresceine
diacetate, Hoechst and Propidium iodide. Apoptotic cells displayed the fragmented chromatin characteristic of the apoptotic process. (B–C) Percentage of apoptotic cells as
measured  48 h later the transfection of sense and antisense oligonucleotides (combination 7 + 9 + 11) in normal and tumoral cell lines is graphed in panel. (D) MTT  cell viability
assay for the HeLa cell line treated with either antisense (ASO) or sense (SO) CSB oligonucleotide (increasing concentration of combination 7 + 9 + 11) followed by an IC50 dose
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gf  oxaliplatin (0.55 M),  mytomicin-C (0.50 g/ml) or 5-ﬂuorouracil (3 g/ml). The
iability relative to the untreated control. (E) MTT  cell viability assay for the C3PV 
increasing concentration of combination 7 + 9 + 11) followed by oxaliplatin (0.55 
ensitized cervix cancer cells (HeLa) to DNA damaging agents such
s oxaliplatin, Mitomicin-C and 5-ﬂuouracil.
Taken together these results shed light on the oncogenic
ole of CSB and open the door for a novel direction in can-
er therapy. Further studies might be envisaged to understand
hether the overexpression of CSB is conﬁned to certain subset
f tumors and/or speciﬁc combinatorial patterns of gene muta-
ions, in addition to the design and screening of new anticancer
rugs that inhibit CSB protein. Additionally, it would be of inter-
st to determine the mechanism by which CSB becomes up
egulated in cancer cells. Genomic rearrangements, including aneu-
loidy and polyploidy, may  account for the increased levels of
SB. Skygrams depicting additional copies of 10q11 locus in the
umoral cells used in our studies appear to conﬁrm this hypoth-
sis (http://www.ncbi.nlm.nih.gov/sky). Further studies will be
ecessary to elucidate the molecular basis for the up regulation
f CSB.Importantly, the inhibition of CSB for cancer therapy also repre-
ents a novel and potentially beneﬁcial avenue of research because
hile most anti-cancer therapies that damage DNA result in the
eneration of secondary tumors due to the DNA damage inﬂicted bynhibition dose IC50 was previously calculated. The results are expressed as percent
l ﬁbroblasts treated with either antisense (ASO) or sense (SO) CSB oligonucleotide
the therapeutic agent to healthy cells, the suppression of CSB avoids
this complication. Alternatively, we can hypothesize that transient
suppression of CSB during a chemotherapy regiment might allow
a reduced dose of chemotherapy agents in order to be less harmful
for healthy cells.
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